Biotech stocks have fallen to earth with a thud in 2021 after soaring last year amid excitement over the development of Covid-19 vaccines, dealing big losses to some hedge funds.
The sector is being buffeted by concerns Congress will move to put a lid on drug pricing and a surfeit of early-stage biotech shares as the IPO market booms.
OpenAI CFO Sarah Friar discusses the corporate's partnership with SoftBank, shoppers embracing synthetic intelligence, OpenAI's 'deep analysis' software and DeepSeek's…
Nationwide, Britain’s greatest constructing society, is kicking off a seek for its…
US Meals CEO Dave Flitman unpacks inflation worries on 'The Claman Countdown.'…
DEAR ABBY: I’ve lately found that my mother-in-law has two…
